Research programme: protein tyrosine phosphatase inhibitors - CEPTYR

Drug Profile

Research programme: protein tyrosine phosphatase inhibitors - CEPTYR

Alternative Names: CPT 633

Latest Information Update: 04 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CEPTYR
  • Developer CEPTYR; Eli Lilly
  • Class
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Feb 2011 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 29 May 2006 A preclinical study with the selected compound CPT 633 has been added to the Type-2 diabetes pharmacodynamics section
  • 11 Jul 2003 The programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top